Professor Keshav K. Singh, one of the world's foremost authorities on mitochondrial biology and genetics, published a breakthrough paper in Cell Death & Disease, one of the Nature journals, that correlated mitochondrial dysfunction to hair thinning.  His startup (Yuva Biosciences) used AI and proprietary information about mitochondria to screen over 14,000 compounds for their ability to restore mitochondrial function.  One of the best performers was YuvaBio's Y200™.

​

YuvaBio was concerned, however, that Y200 had poor penetration and a short duration-of-effect on mitochondrial function.  Thus, they turned to Zylö’s Z-pod® technology, which provides science-backed sustained release and provides deeper penetration into hair follicles. (see image nearby--the Z-pods, which are red-labeled and applied to ex vivo human skin, penetrate deep into the stratum corneum and into follicles).  

 

Atticus Pharma has license agreements with both YuvaBio and Zylö to advance YuvaBio-Y200-loaded Z-pods® for the treatment of androgenic alopecia.